0RHR Stock Overview
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF7.50 |
| 52 Week High | CHF8.28 |
| 52 Week Low | CHF1.33 |
| Beta | 0.91 |
| 1 Month Change | 37.77% |
| 3 Month Change | 68.62% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | 185.30% |
| Change since IPO | -73.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RHR | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.8% | 0.5% | 2.7% |
| 1Y | n/a | -29.8% | 0.3% |
Return vs Industry: Insufficient data to determine how 0RHR performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0RHR performed against the UK Market.
Price Volatility
| 0RHR volatility | |
|---|---|
| 0RHR Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RHR's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0RHR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 80 | Chris Fair | www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Kuros Biosciences AG Fundamentals Summary
| 0RHR fundamental statistics | |
|---|---|
| Market cap | CHF262.00m |
| Earnings (TTM) | -CHF13.73m |
| Revenue (TTM) | CHF33.56m |
7.8x
P/S Ratio-19.1x
P/E RatioIs 0RHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RHR income statement (TTM) | |
|---|---|
| Revenue | CHF33.56m |
| Cost of Revenue | CHF10.69m |
| Gross Profit | CHF22.87m |
| Other Expenses | CHF36.60m |
| Earnings | -CHF13.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 68.14% |
| Net Profit Margin | -40.90% |
| Debt/Equity Ratio | 0% |
How did 0RHR perform over the long term?
See historical performance and comparison